SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sherwin Williams Co. – ‘10-Q’ for 3/31/21 – ‘R18’

On:  Wednesday, 4/28/21, at 2:07pm ET   ·   For:  3/31/21   ·   Accession #:  89800-21-16   ·   File #:  1-04851

Previous ‘10-Q’:  ‘10-Q’ on 10/27/20 for 9/30/20   ·   Next:  ‘10-Q’ on 7/27/21 for 6/30/21   ·   Latest:  ‘10-Q’ on 4/30/24 for 3/31/24   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/28/21  Sherwin Williams Co.              10-Q        3/31/21   78:6.3M

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    685K 
 2: EX-10.1     Material Contract                                   HTML     20K 
 3: EX-31.A     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-31.B     Certification -- §302 - SOA'02                      HTML     25K 
 5: EX-32.A     Certification -- §906 - SOA'02                      HTML     22K 
 6: EX-32.B     Certification -- §906 - SOA'02                      HTML     22K 
13: R1          Cover Page                                          HTML     71K 
14: R2          Statements of Consolidated Income (Unaudited)       HTML     86K 
15: R3          Statements of Consolidated Comprehensive Income     HTML     50K 
                (Unaudited)                                                      
16: R4          Statements of Consolidated Comprehensive Income     HTML     32K 
                (Unaudited) (Parenthetical)                                      
17: R5          Consolidated Balance Sheets (Unaudited)             HTML    111K 
18: R6          Consolidated Balance Sheets (Unaudited)             HTML     24K 
                (Parenthetical)                                                  
19: R7          Condensed Statements of Consolidated Cash Flows     HTML    119K 
                (Unaudited)                                                      
20: R8          Statements of Consolidated??Shareholders' Equity    HTML     69K 
                (Unaudited)                                                      
21: R9          Statements of Consolidated??Shareholders' Equity    HTML     22K 
                (Parenthetical)                                                  
22: R10         Basis of Presentation                               HTML     25K 
23: R11         Recently Issued Accounting Pronouncements           HTML     29K 
24: R12         Acquisitions and Divestitures                       HTML     23K 
25: R13         Inventories                                         HTML     30K 
26: R14         Goodwill, Intangible and Long-Lived Assets          HTML     39K 
27: R15         Debt                                                HTML     23K 
28: R16         Pension and Other Postretirement Benefits           HTML     58K 
29: R17         Other Long-Term Liabilities                         HTML     37K 
30: R18         Litigation                                          HTML     49K 
31: R19         Shareholders' Equity                                HTML     23K 
32: R20         Accumulated Other Comprehensive (Loss) Income       HTML     45K 
33: R21         Derivatives and Hedging                             HTML     31K 
34: R22         Fair Value Measurements                             HTML     68K 
35: R23         Revenue                                             HTML     47K 
36: R24         Other                                               HTML     45K 
37: R25         Income Taxes                                        HTML     26K 
38: R26         Net Income Per Share                                HTML     40K 
39: R27         Reportable Segment Information                      HTML     84K 
40: R28         Non-Traded Investments                              HTML     29K 
41: R29         Basis of Presentation (Policies)                    HTML     27K 
42: R30         Inventories (Tables)                                HTML     31K 
43: R31         Goodwill, Intangible and Long-Lived Assets          HTML     36K 
                (Tables)                                                         
44: R32         Pension and Other Postretirement Benefits (Tables)  HTML     57K 
45: R33         Accumulated Other Comprehensive (Loss) Income       HTML     44K 
                (Tables)                                                         
46: R34         Derivatives and Hedging (Tables)                    HTML     29K 
47: R35         Fair Value Measurements (Tables)                    HTML     65K 
48: R36         Revenue (Tables)                                    HTML     39K 
49: R37         Other (Tables)                                      HTML     45K 
50: R38         Net Income Per Share (Tables)                       HTML     40K 
51: R39         Reportable Segment Information (Tables)             HTML     68K 
52: R40         Non-Traded Investments (Tables)                     HTML     32K 
53: R41         Basis of Presentation (Details)                     HTML     22K 
54: R42         Acquisitions and Divestitures (Details)             HTML     31K 
55: R43         Inventories (Details)                               HTML     27K 
56: R44         Goodwill, Intangible and Long-Lived Assets          HTML     37K 
                (Details)                                                        
57: R45         Debt (Details)                                      HTML     44K 
58: R46         Pension and Other Postretirement Benefits           HTML     55K 
                (Details)                                                        
59: R47         Other Long-Term Liabilities (Details)               HTML     53K 
60: R48         Litigation (Details)                                HTML     84K 
61: R49         Shareholders' Equity (Details)                      HTML     40K 
62: R50         Accumulated Other Comprehensive (Loss) Income       HTML     40K 
                (Details)                                                        
63: R51         Derivatives and Hedging (Details)                   HTML     50K 
64: R52         Fair Value Measurements (Details)                   HTML     65K 
65: R53         REVENUE - Narrative (Details)                       HTML     22K 
66: R54         Revenue (Details)                                   HTML     62K 
67: R55         OTHER - Other General Expense - Net (Details)       HTML     29K 
68: R56         OTHER - Other (Income) Expense - Net (Details)      HTML     37K 
69: R57         OTHER - Narrative (Details)                         HTML     23K 
70: R58         Income Taxes (Details)                              HTML     31K 
71: R59         Net Income Per Share (Details)                      HTML     59K 
72: R60         REPORTABLE SEGMENT INFORMATION - Narrative          HTML     36K 
                (Details)                                                        
73: R61         REPORTABLE SEGMENT INFORMATION - Reportable         HTML     60K 
                Segment Information (Details)                                    
74: R62         Non-Traded Investments (Details)                    HTML     30K 
76: XML         IDEA XML File -- Filing Summary                      XML    135K 
12: XML         XBRL Instance -- shw-20210331_htm                    XML   1.52M 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX     87K 
 8: EX-101.CAL  XBRL Calculations -- shw-20210331_cal                XML    209K 
 9: EX-101.DEF  XBRL Definitions -- shw-20210331_def                 XML    411K 
10: EX-101.LAB  XBRL Labels -- shw-20210331_lab                      XML   1.33M 
11: EX-101.PRE  XBRL Presentations -- shw-20210331_pre               XML    723K 
 7: EX-101.SCH  XBRL Schema -- shw-20210331                          XSD    137K 
77: JSON        XBRL Instance as JSON Data -- MetaLinks              368±   501K 
78: ZIP         XBRL Zipped Folder -- 0000089800-21-000016-xbrl      Zip    240K 


‘R18’   —   Litigation


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.21.1
LITIGATION
3 Months Ended
Commitments and Contingencies Disclosure [Abstract]  
LITIGATION LITIGATION
In the course of its business, the Company is subject to a variety of claims and lawsuits, including, but not limited to, litigation relating to product liability and warranty, personal injury, environmental, intellectual property, commercial, contractual and antitrust claims that are inherently subject to many uncertainties regarding the possibility of a loss to the Company. These uncertainties will ultimately be resolved when one or more future events occur or fail to occur confirming the incurrence of a liability or the reduction of a liability. In accordance with the Contingencies Topic of the ASC, the Company accrues for these contingencies by a charge to income when it is both probable that one or more future events will occur confirming the fact of a loss and the amount of the loss can be reasonably estimated. In the event that the Company’s loss contingency is ultimately determined to be significantly higher than currently accrued, the recording of the additional liability may result in a material impact on the Company’s results of operations, liquidity or financial condition for the annual or interim period during which such additional liability is accrued. In those cases where no accrual is recorded because it is not probable that a liability has been incurred and the amount of any such loss cannot be reasonably estimated, any potential liability ultimately determined to be attributable to the Company may result in a material impact on the Company’s results of operations, liquidity or financial condition for the annual or interim period during which such liability is accrued. In those cases where no accrual is recorded or exposure to loss exists in excess of the amount accrued, the Contingencies Topic of the ASC requires disclosure of the contingency when there is a reasonable possibility that a loss or additional loss may have been incurred.
Lead pigment and lead-based paint litigation. The Company’s past operations included the manufacture and sale of lead pigments and lead-based paints. The Company, along with other companies, is and has been a defendant in a number of legal proceedings, including individual personal injury actions, purported class actions, and actions brought by various counties, cities, school districts and other government-related entities, arising from the manufacture and sale of lead pigments and lead-based paints. The plaintiffs’ claims have been based upon various legal theories, including negligence, strict liability, breach of warranty, negligent misrepresentations and omissions, fraudulent misrepresentations and omissions, concert of action, civil conspiracy, violations of unfair trade practice and consumer protection laws, enterprise liability, market share liability, public
nuisance, unjust enrichment and other theories. The plaintiffs seek various damages and relief, including personal injury and property damage, costs relating to the detection and abatement of lead-based paint from buildings, costs associated with a public education campaign, medical monitoring costs and others. The Company has also been a defendant in legal proceedings arising from the manufacture and sale of non-lead-based paints that seek recovery based upon various legal theories, including the failure to adequately warn of potential exposure to lead during surface preparation when using non-lead-based paint on surfaces previously painted with lead-based paint. The Company believes that the litigation brought to date is without merit or subject to meritorious defenses and is vigorously defending such litigation. The Company expects that additional lead pigment and lead-based paint litigation may be filed against the Company in the future asserting similar or different legal theories and seeking similar or different types of damages and relief. The Company will continue to vigorously defend against any additional lead pigment and lead-based paint litigation that may be filed, including utilizing all avenues of appeal, if necessary.
Notwithstanding the Company’s views on the merits, litigation is inherently subject to many uncertainties, and the Company ultimately may not prevail. Adverse court rulings or determinations of liability, among other factors, could affect the lead pigment and lead-based paint litigation against the Company and encourage an increase in the number and nature of future claims and proceedings. In addition, from time to time, various legislation and administrative regulations have been enacted, promulgated or proposed to impose obligations on present and former manufacturers of lead pigments and lead-based paints respecting asserted health concerns associated with such products or to overturn the effect of court decisions in which the Company and other manufacturers have been successful.
Due to the uncertainties involved, management is unable to predict the outcome of the lead pigment and lead-based paint litigation, the number or nature of possible future claims and proceedings or the effect that any legislation and/or administrative regulations may have on the litigation or against the Company. In addition, management cannot reasonably determine the scope or amount of the potential costs and liabilities related to such litigation, or resulting from any such legislation and regulations. Except with respect to the litigation in California discussed below, the Company has not accrued any amounts for such litigation because the Company does not believe it is probable that a loss has occurred, and the Company believes it is not possible to estimate the range of potential losses as there is no substantive information upon which an estimate could be based. In addition, any potential liability that may result from any changes to legislation and regulations cannot reasonably be estimated. Due to the uncertainties associated with the amount of any such liability and/or the nature of any other remedy which may be imposed in such litigation, any potential liability determined to be attributable to the Company arising out of such litigation may have a material adverse effect on the Company’s results of operations, liquidity or financial condition. An estimate of the potential impact on the Company’s results of operations, liquidity or financial condition cannot be made due to the aforementioned uncertainties.
Public Nuisance Claim Litigation. The Company and other companies are or were defendants in legal proceedings seeking recovery based on public nuisance liability theories, among other theories, brought by the State of Rhode Island; the City of St. Louis, Missouri; various cities and counties in the State of New Jersey; various cities in the State of Ohio and the State of Ohio; the City of Chicago, Illinois; the City of Milwaukee, Wisconsin; the County of Santa Clara, California, and other public entities in the State of California; and Lehigh and Montgomery Counties in Pennsylvania. Except for the Santa Clara County, California proceeding and the pending Pennsylvania proceedings, all of these legal proceedings have been concluded in favor of the Company and other defendants at various stages in the proceedings.
Santa Clara County, California Proceeding. The Santa Clara County, California proceeding was initiated in March 2000 in the Superior Court of the State of California, County of Santa Clara. On July 17, 2019, after nearly twenty years of litigation, the Company and two other defendants (ConAgra Grocery Products Company and NL Industries, Inc.) reached an agreement in principle with the plaintiffs to resolve the litigation. The agreement provides that, in full and final satisfaction of any and all claims of the plaintiffs, the defendants collectively shall pay a total of $305.0 million, with the defendants each paying approximately $101.7 million as follows: (i) an initial payment of $25.0 million within sixty days after the entry of a dismissal order and judgment; (ii) subsequent annual payments of $12.0 million one year after the initial payment and for a period of four years thereafter; and (iii) a final payment of approximately $16.7 million on the sixth anniversary of the initial payment. Should NL Industries fail to make any of its payments required under the agreement, the Company has agreed to backstop and pay on behalf of NL Industries a maximum amount of $15.0 million. On July 24, 2019, the trial court approved the agreement, discharged the receiver, and granted a judgment of dismissal with prejudice in favor of the defendants. At March 31, 2021 and 2020, the Company had accruals for this agreement reported on the balance sheet of $64.7 million and $76.7 million, respectively, with $12.0 million included in Current liabilities and the remaining $52.7 million and $64.7 million, respectively, included in Other long-term liabilities.
Pennsylvania Proceedings. Two proceedings in Pennsylvania were initiated in October 2018. The Pennsylvania counties of Montgomery and Lehigh filed complaints against the Company and several other former lead-based paint and lead pigment manufacturers in the Courts of Common Pleas of Montgomery County, Pennsylvania and Lehigh County, Pennsylvania, respectively. In both actions, the counties request declaratory relief establishing the existence of a public nuisance and the
defendants' contribution to it, the abatement of an ongoing public nuisance arising from the presence of lead-based paint in housing throughout the applicable county, an injunction against future illicit conduct, and the costs of litigation and attorneys' fees. After the defendants removed the actions to federal court and the actions were remanded to state court, the defendants filed preliminary objections on December 21, 2020, seeking to dismiss the complaints with prejudice. The briefing associated with the preliminary objections concluded on February 23, 2021. Oral argument for the Lehigh County action occurred on April 14, 2021. The parties are awaiting the courts’ decisions.
In October 2018, the Company filed a complaint in the United States District Court for the Eastern District of Pennsylvania against the Pennsylvania Counties of Delaware, Erie and York seeking injunctive and declaratory relief to prevent the violation of the Company's rights under the First Amendment and Due Process Clause of the U.S. Constitution. The Company voluntarily dismissed defendants Erie County and York County in November 2018. Defendant Delaware County filed a motion to dismiss the complaint, which the federal trial court granted on October 4, 2019. The Company appealed the federal trial court’s dismissal on November 1, 2019 to the United States Court of Appeals for the Third Circuit. On July 31, 2020, the Third Circuit affirmed the federal trial court's dismissal of the complaint. The Company filed a petition for writ of certiorari to the United States Supreme Court on December 28, 2020. The United States Supreme Court denied the Company’s petition on April 26, 2021.
Litigation seeking damages from alleged personal injury. The Company and other companies are defendants in a number of legal proceedings seeking monetary damages and other relief from alleged personal injuries. These proceedings include claims by children allegedly injured from ingestion of lead pigment or lead-containing paint and claims for damages allegedly incurred by the children’s parents or guardians. These proceedings generally seek compensatory and punitive damages, and seek other relief including medical monitoring costs. These proceedings include purported claims by individuals, groups of individuals and class actions.
The plaintiff in Thomas v. Lead Industries Association, et al., initiated an action in Wisconsin state court against the Company, other alleged former lead pigment manufacturers and the Lead Industries Association in September 1999. The claims against the defendants included strict liability, negligence, negligent misrepresentation and omissions, fraudulent misrepresentation and omissions, concert of action, civil conspiracy and enterprise liability. Implicit within these claims is the theory of “risk contribution” liability (Wisconsin’s theory which is similar to market share liability, except that liability can be joint and several) due to the plaintiff’s inability to identify the manufacturer of any product that allegedly injured the plaintiff. The case ultimately proceeded to trial and, on November 5, 2007, the jury returned a defense verdict, finding that the plaintiff had ingested white lead carbonate, but was not brain damaged or injured as a result. The plaintiff appealed and, on December 16, 2010, the Wisconsin Court of Appeals affirmed the final judgment in favor of the defendants.
Wisconsin is the only jurisdiction to date to apply a theory of liability with respect to alleged personal injury (i.e., risk contribution/market share liability) that does not require the plaintiff to identify the manufacturer of the product that allegedly injured the plaintiff in the lead pigment and lead-based paint litigation. Although the risk contribution liability theory was applied during the Thomas trial, the constitutionality of this theory as applied to the lead pigment cases has not been judicially determined by the Wisconsin state courts. However, in an unrelated action filed in the United States District Court for the Eastern District of Wisconsin, Gibson v. American Cyanamid, et al., on November 15, 2010, the District Court held that Wisconsin’s risk contribution theory as applied in that case violated the defendants’ right to substantive due process and is unconstitutionally retroactive. The District Court's decision in Gibson v. American Cyanamid, et al., was appealed by the plaintiff to the United States Court of Appeals for the Seventh Circuit. On July 24, 2014, the United States Court of Appeals for the Seventh Circuit reversed the judgment and remanded the case back to the District Court for further proceedings. On January 16, 2015, the defendants filed a petition for certiorari in the United States Supreme Court seeking that Court's review of the Seventh Circuit's decision, and on May 18, 2015, the United States Supreme Court denied the defendants' petition. The case is currently pending in the District Court.
The United States District Court for the Eastern District of Wisconsin consolidated three cases (Ravon Owens v. American Cyanamid, et al., Cesar Sifuentes v. American Cyanamid, et al., and Glenn Burton, Jr. v. American Cyanamid, et al.) for purposes of trial. A trial was held in May 2019 and resulted in a jury verdict for the three plaintiffs in the amount of $2.0 million each for a total of $6.0 million against the Company and two other defendants (Armstrong Containers Inc. and E.I. du Pont de Nemours). The Company filed a motion for judgment in its favor based on public policy factors under Wisconsin law. On September 20, 2019, the trial court denied the motion and entered judgment in favor of the plaintiffs. On October 18, 2019, the Company filed post-trial motions for judgment as a matter of law and for a new trial. On February 27, 2020, the trial court denied the Company's post-trial motion for judgment as a matter of law. On April 10, 2020, the trial court granted the Company's post-trial motion for a new trial to the extent that the damages award to plaintiff Glenn Burton, Jr. shall be remitted to $800,000, and denied the motion in all other respects. On May 8, 2020, the Company filed a notice of appeal with the United States Court of Appeals for the Seventh Circuit. On April 15, 2021, the Seventh Circuit reversed the judgments and held that the Company was entitled to judgment as a matter of law. The plaintiffs filed a petition with the Seventh Circuit on April 27,
2021, seeking a rehearing en banc and, in the alternative, a request for certification of questions to the Wisconsin Supreme Court.
In Maniya Allen, et al. v. American Cyanamid, et al., also pending in the United States District Court for the Eastern District of Wisconsin, cases involving six of the 146 plaintiffs were selected for discovery. In Dijonae Trammell, et al. v. American Cyanamid, et al., also pending in the United States District Court for the Eastern District of Wisconsin, discovery for one of the three plaintiffs was consolidated with the six Allen cases referenced above. The parties selected four of the cases to proceed to expert discovery and to prepare for trial. The District Court previously issued an order scheduling trial in the four cases to commence on June 15, 2020, but the trial date was continued due to the COVID-19 pandemic, and no new trial date has been scheduled.
Other lead-based paint and lead pigment litigation. In Mary Lewis v. Lead Industries Association, et al. pending in the Circuit Court of Cook County, Illinois, parents seek to recover the cost of their children’s blood lead testing against the Company and three other defendants that made (or whose alleged corporate predecessors made) white lead pigments. The Circuit Court has certified a statewide class and a Chicago subclass of parents or legal guardians of children who lived in high-risk zip codes identified by the Illinois Department of Health and who were screened for lead toxicity between August 1995 and February 2008. Excluded from the class are those parents or guardians who have incurred no expense, liability or obligation to pay for the cost of their children’s blood lead testing. In 2017, the defendants moved for summary judgment on the grounds that the three named plaintiffs have not paid and have no obligation or liability to pay for their children’s blood lead testing because Medicaid paid for the children of two plaintiffs and private insurance paid for the third plaintiff without any evidence of a co-pay or deductible. The Circuit Court granted the motion, but on September 7, 2018, the Appellate Court reversed with respect to the two plaintiffs for whom Medicaid paid for their children’s testing. Defendants appealed to the Supreme Court of Illinois, and on May 21, 2020, the Supreme Court reversed the Appellate Court's judgment, affirmed the Circuit Court's summary judgment dismissing the claims of the two plaintiffs for whom Medicaid paid for their children's testing, and remanded the case for further proceedings consistent with the Supreme Court's decision. On August 19, 2020, the defendants filed their renewed motion for class decertification and entry of final judgment with the Circuit Court. The parties filed their respective briefs on the motion, and oral argument occurred on February 4, 2021. The parties are awaiting the Circuit Court’s decision.
On March 8, 2021, the Illinois Department of Healthcare and Family Services filed a petition to intervene and a proposed amended complaint, which would eliminate the class and all prior claims by individual plaintiffs and would propose a subrogation claim by the State agency to recover its expenditures for blood lead testing. Defendants’ response to the petition is due on April 30, 2021, and the intervener plaintiff’s reply is due on May 17, 2021.

Insurance coverage litigation. The Company and its liability insurers, including certain underwriters at Lloyd’s of London, initiated legal proceedings against each other to determine, among other things, whether the costs and liabilities associated with the abatement of lead pigment are covered under certain insurance policies issued to the Company. The liability insurers’ action, which was filed on February 23, 2006 in the Supreme Court of the State of New York, County of New York, has been dismissed.

The Company’s action, filed on March 3, 2006 in the Common Pleas Court, Cuyahoga County, Ohio, previously was stayed and inactive. On January 9, 2019, the Company filed an unopposed motion to lift the stay with the trial court, which was granted, allowing the case to proceed. On June 28, 2019, the Company and its liability insurers each filed separate motions for summary judgment seeking various forms of relief. The trial court entered an order on December 4, 2020, granting the liability insurers’ motion for summary judgment, denying the Company’s motion, and entering final judgment in favor of the liability insurers. The trial court sided with the Company on all of the issues presented, except one. On December 21, 2020, the Company filed a notice of appeal to the Court of Appeals of Cuyahoga County, Ohio, Eighth Appellate District, and the liability insurers filed cross-appeals. Briefing on the issues is scheduled to conclude in the spring of 2021.
An ultimate loss in the insurance coverage litigation would mean that insurance proceeds could be unavailable under the policies at issue to mitigate any ultimate abatement related costs and liabilities. The Company has not recorded any assets related to these insurance policies or otherwise assumed that proceeds from these insurance policies would be received in estimating any contingent liability accrual. Therefore, an ultimate loss in the insurance coverage litigation without a determination of liability against the Company in the lead pigment or lead-based paint litigation will have no impact on the Company’s results of operation, liquidity or financial condition. As previously stated, however, except with respect to the litigation in California discussed above, the Company has not accrued any amounts for the lead pigment or lead-based paint litigation and any significant liability ultimately determined to be attributable to the Company relating to such litigation may result in a material impact on the Company’s results of operations, liquidity or financial condition for the annual or interim period during which such liability is accrued.
Other litigation. On December 18, 2019, the New Jersey Department of Environmental Protection, the Commissioner of the New Jersey Department of Environmental Protection, and the Administrator of the New Jersey Spill Compensation Fund filed a lawsuit against the Company in the Superior Court of New Jersey Law Division in Camden County, New Jersey. The plaintiffs seek to recover natural resource damages, punitive damages, and litigation fees and costs, as well as other costs, damages, declaratory relief, and penalties pursuant to New Jersey state statutes and common law theories in connection with the alleged discharge of hazardous substances and pollutants at the Company’s Gibbsboro, New Jersey site, a former manufacturing plant and related facilities. On February 21, 2020, the Company filed a motion to dismiss. On April 7, 2020, the plaintiffs filed a brief in opposition. The Company filed a reply brief on April 20, 2020. An initial hearing on the motion to dismiss occurred on January 29, 2021. The hearing is scheduled to continue on July 13-14, 2021.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
5/17/21
4/30/21
Filed on:4/28/21
4/27/218-K
4/26/218-K
4/15/21
4/14/21
For Period end:3/31/21
3/8/213,  4
2/23/21
2/4/21
1/29/21
12/28/20
12/21/20
12/4/20
8/19/20
7/31/204
6/15/20
5/21/204
5/8/204
4/20/20
4/10/20
4/7/204
3/31/2010-Q
2/27/20
2/21/2010-K
12/18/19
11/1/194
10/18/194
10/4/194
9/20/19
7/24/1910-Q,  4
7/17/194
6/28/198-K
1/9/19
9/7/18
5/18/15
1/16/15
7/24/1410-Q
12/16/10
11/15/103,  4
11/5/07
3/3/06
2/23/063,  4,  4/A
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/10/21  Sherwin-Williams Co.              424B5                  1:572K                                   Donnelley … Solutions/FA
11/08/21  Sherwin-Williams Co.              424B5                  1:568K                                   Donnelley … Solutions/FA


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/03/21  Sherwin-Williams Co.              8-K:5,9     3/03/21   11:146K                                   Donnelley … Solutions/FA
Top
Filing Submission 0000089800-21-000016   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 1:16:20.1pm ET